SCHEMBL223352

SCHEMBL223352

CC(C(=O)O)(C(=O)O)c1ccc2c(c1C(=O)O)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.50
ALDH1A1 P00352 3/20 0.50
ALOX12 P18054 3/20 0.50
CYP2C9 P11712 2/20 0.50
ALOX15 P16050 2/20 0.50
BRCA1 P38398 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FTO Q9C0B1 10/20 0.49
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
HTT P42858 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
SMAD3 P84022 1/20 0.49
PRMT1 Q99873 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989053 0.83 HPGD (0.53) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL6037012 0.82 ALDH1A1 (0.56) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL6535901 0.81 HPGD (0.55) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL2877720 0.79 HPGD (0.51) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL3282095 0.79 HPGD (0.51) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL2407742 0.78 HPGD (0.52) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL1986259 0.77 HPGD (0.49) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL4802179 0.77 HPGD (0.51) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL213292 0.76 HPGD (0.53) HPGDALDH1A1ALOX12CYP2C9ALOX15
SCHEMBL7907421 0.76 ALDH1A1 (0.53) HPGDALDH1A1ALOX12CYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2684963-B1 METHOD FOR SCREENING FOR COMPOUND CAPABLE OF ENHANCING OR INHIBITING OATP1B1 TRANSPORT ACTIVITY, AND METHOD FOR DETERMINING EXPRESSION LEVEL OF OATP1B1 EISAI R&D MAN CO LTD (JP) 2016-02-03 EP disclosed
EP-2684963-A1 METHOD FOR SCREENING FOR COMPOUND CAPABLE OF ENHANCING OR INHIBITING OATP1B1 TRANSPORT ACTIVITY, AND METHOD FOR DETERMINING EXPRESSION LEVEL OF OATP1B1 Eisai R&D Management Co., Ltd. (JP) 2014-01-15 EP disclosed
US-20120003639-A1 CANCER BIOMARKERS AND METHODS OF USE THEREOF PRELUDE, INC. (US) 2012-01-05 US disclosed
US-7910097-B2 Lymphatic endothelial glycoprotein for use as tool in identifying modulators for prevention and treatment of inflammation and cell proliferative disorders FARON PHARMACEUTICALS OY (FI) 2011-03-22 US disclosed
US-20090191131-A1 USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMATERS FOSSHEIM SIGRID LISE 2009-07-30 US disclosed
WO-2009010766-A1 METHOD UNIVERSITY OF THE WEST OF ENGLAND, BRISTOL (GB) 2009-01-22 WO disclosed
US-20080267958-A1 Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof FARON PHARMACEUTICALS OY 2008-10-30 US disclosed
US-7354577-B2 Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof FARON PHARMACEUTICALS OY (FI) 2008-04-08 US disclosed
EP-1463760-B1 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF FARON PHARMACEUTICALS OY (FI) 2007-09-05 EP disclosed
US-20050136002-A1 Use of particulate contrast agents in diagnostic imaging for studying physiological paramaters GE HEALTHCARE AS (NO) 2005-06-23 US disclosed
US-20050069888-A1 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof FARON PHARMACEUTICALS OY (FI) 2005-03-31 US disclosed
EP-1463760-A2 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF JALKANEN, Sirpa (FI) 2004-10-06 EP disclosed
EP-1069888-B1 USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMETERS AMERSHAM HEALTH AS (NO) 2004-09-22 EP disclosed
WO-2003057130-A2 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF JALKANEN SIRPA (FI) 2003-07-17 WO disclosed
EP-1100956-A2 PROCESS FOR IDENTIFICATION OF SUBSTANCES MODULATING UREI DEPENDENT MECHANISMS OF HELICOBACTER PYLORI METABOLISM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-05-23 EP disclosed
WO-2000008204-A2 PROCESS FOR IDENTIFICATION OF SUBSTANCES MODULATING UREI DEPENDENT MECHANISMS OF HELICOBACTER PYLORI METABOLISM BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-02-17 WO disclosed
US-5942409-A Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-08-24 US disclosed
US-4945171-A FLUORESCENT DYES MOLECULAR PROBES, INC. (US) 1990-07-31 US disclosed
EP-0221768-A2 Detection of T-cell activation DANA-FARBER CANCER INSTITUTE, INC. (US) 1987-05-13 EP disclosed